Saline Hypertonic in Preschoolers

NCT ID: NCT02378467

Last Updated: 2020-01-14

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 150 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-03-01
• Study Completion Date: 2018-08-31

Brief Summary

The purpose of this study is to assess whether inhalation of 7% hypertonic saline (HS) twice daily for 48 weeks improves the lung clearance index by multiple breath nitrogen washout in comparison with inhalation of 0.9% isotonic saline (IS) in preschool children (ages 3 to 5) with cystic fibrosis.

Detailed Description

A growing body of evidence supports the importance of intervention in cystic fibrosis (CF) lung disease during early childhood, in order to potentially delay or prevent irreversible lung damage. Yet, aside from antimicrobial therapies, the CF community has no clinical trial evidence base with which to guide chronic pulmonary therapies in preschool children. Hypertonic saline (HS) is the most attractive chronic maintenance therapy to investigate in preschool children because it addresses defective mucociliary clearance, an early step in the cascade of events leading to CF lung disease that is expected to be abnormal prior to the onset of airway infection and inflammation.

Based on several studies, HS appears to be safe in children less than 6 years of age, but its effectiveness has been difficult to measure. In a previous study (ISIS), children less than 6 years old receiving HS had the same number of lung infections as children receiving a control treatment. However, the investigators think that children this young need a more sensitive test, such as lung function testing, to see if HS works in preventing lung damage. Multiple Breath Washout (MBW) is a relatively easy lung function test to perform with preschool children. It calculates a measurement called the Lung Clearance Index (LCI), a sensitive measure of airway inhomogeneity. In a sub-study of the ISIS study in 25 children, LCI improved in children that inhaled HS twice daily for 48 weeks.

This is a multicenter, randomized, double-blind, controlled, parallel group trial assessing LCI in children with CF ages 3 to 5 at enrollment. Participants will be randomized 1:1 to receive 7% HS (treatment arm) vs. 0.9 % isotonic saline (control arm) administered twice daily via jet nebulizer for 48 weeks. Study visits will occur at Screening, Enrollment, and at Weeks 12, 24, 36 and 48. Contact with a parent or legal guardian to assess adherence and interim medical history will occur at 1, 4 and 8 weeks after enrollment and then quarterly between subsequent study visits. Except for the screening visit, study visits will occur on a quarterly basis.

Total duration of participation will be up to 52 weeks. As enrollment will occur over approximately 18 months, total duration of the study is expected to be up to 30 months (18 months enrollment plus 12 months for the last participants to complete study participation).

Conditions

Cystic Fibrosis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Active Treatment Group

7% Hypertonic Saline administered via inhalation twice daily for 48 weeks

Group Type: EXPERIMENTAL

7% Hypertonic Saline (HS)

Intervention Type: DRUG

Administered via inhalation twice daily for 48 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Vios® compressor.

Control Group

0.9% Isotonic Saline administered via inhalation twice daily for 48 weeks

Group Type: ACTIVE_COMPARATOR

0.9% Isotonic Saline (IS)

Intervention Type: DRUG

Administered via inhalation twice daily for 48 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Vios® compressor.

Interventions

7% Hypertonic Saline (HS)

Administered via inhalation twice daily for 48 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Vios® compressor.

Intervention Type: DRUG

0.9% Isotonic Saline (IS)

Administered via inhalation twice daily for 48 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Vios® compressor.

Intervention Type: DRUG

Other Intervention Names

Hyper-Sal™, inhaled saline; Normal saline

Eligibility Criteria

Inclusion Criteria

• Diagnosis of CF as evidenced by one or more clinical feature consistent with the CF phenotype or positive CF newborn screen AND one or more of the following criteria:
• A documented sweat chloride ≥ 60 milliequivalents of solute per litre (mEq/L) by quantitative pilocarpine iontophoresis (QPIT)
• A documented genotype with two disease-causing mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene
• Informed consent by parent or legal guardian
• Age ≥ 36 months and ≤72 months at Screening visit
• Ability to comply with medication use, study visits and study procedures as judged by the site investigator
• Ability to perform technically acceptable MBW measurements at the screening and enrollment visits

Exclusion Criteria

• Acute intercurrent respiratory infection, defined as an increase in cough, wheezing, or respiratory rate with onset within 3 weeks preceding Screening or Enrollment visit
• Acute wheezing at Screening or Enrollment visit
• Oxygen saturation < 95% (<90% in centers located above 4000 feet elevation) at Screening or Enrollment visit
• Physical findings that would compromise the safety of the participant or the quality of the study data as determined by site investigator
• Investigational drug use within 30 days prior to Screening or Enrollment visit
• Treatment with inhaled hypertonic saline at any concentration within 30 days prior to Screening or Enrollment visit
• Chronic lung disease not related to CF
• Inability to tolerate first dose of study treatment at the Enrollment visit

• Minimum Eligible Age: 3 Years
• Maximum Eligible Age: 5 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Cystic Fibrosis Foundation

OTHER

Sponsor Role: collaborator

University of Washington, the Collaborative Health Studies Coordinating Center

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Felix Ratjen, MD, PhD, FRCPC

Role: PRINCIPAL_INVESTIGATOR

Hospital for Sick Kids, Toronto

Margaret Rosenfeld, MD, MPH

Role: PRINCIPAL_INVESTIGATOR

Seattle Children's Hospital

Stephanie Davis, MD

Role: PRINCIPAL_INVESTIGATOR

Indiana University

Richard A Kronmal, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Washington

Locations

University of Alabama-Birmingham: Pulmonary, Allergy and Critical Care Medicine

Birmingham, Alabama, United States

Stanford University

Palo Alto, California, United States

Children's Hospital of Colorado

Aurora, Colorado, United States

Nemours Children's Hospital

Orlando, Florida, United States

Ann & Robert H. Lurie Children's Hospital of Chicago

Chicago, Illinois, United States

Riley Hospital for Children-Indiana U Med Center

Indianapolis, Indiana, United States

University of Iowa, Department of Pediatrics

Iowa City, Iowa, United States

Johns Hopkins University: Pediatric Pulmonary

Baltimore, Maryland, United States

Boston Children's Hospital

Boston, Massachusetts, United States

Children's Hospitals and Clinics of Minnesota

Minneapolis, Minnesota, United States

Children's Mercy Hospital

Kansas City, Missouri, United States

Washington University School of Medicine

St Louis, Missouri, United States

Women & Children's Hospital of Buffalo

Buffalo, New York, United States

University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, United States

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States

Rainbow Babies Children's Hospital and Case Western Reserve University School of Medicine

Cleveland, Ohio, United States

Nationwide Children's Hospital

Columbus, Ohio, United States

Oregon Health Sciences University

Portland, Oregon, United States

Children's Hospital of Philadelphia, UPenn

Philadelphia, Pennsylvania, United States

Children's Hospital of Pittsburgh of UPMC

Pittsburgh, Pennsylvania, United States

Texas Children's Hospital and Baylor College of Medicine

Houston, Texas, United States

Seattle Children's Hospital

Seattle, Washington, United States

Children's Hospital of Wisconsin

Milwaukee, Wisconsin, United States

British Columbia Children's Hospital

Vancouver, British Columbia, Canada

Hospital for Sick Kids

Toronto, Ontario, Canada

Countries

United States; Canada

References

Rosenfeld M, Ratjen F, Brumback L, Daniel S, Rowbotham R, McNamara S, Johnson R, Kronmal R, Davis SD; ISIS Study Group. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA. 2012 Jun 6;307(21):2269-77. doi: 10.1001/jama.2012.5214.

Reference Type: BACKGROUND

PMID: 22610452 (View on PubMed)

Amin R, Subbarao P, Jabar A, Balkovec S, Jensen R, Kerrigan S, Gustafsson P, Ratjen F. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax. 2010 May;65(5):379-83. doi: 10.1136/thx.2009.125831.

Reference Type: BACKGROUND

PMID: 20435858 (View on PubMed)

Ratjen F, Davis SD, Stanojevic S, Kronmal RA, Hinckley Stukovsky KD, Jorgensen N, Rosenfeld M; SHIP Study Group. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2019 Sep;7(9):802-809. doi: 10.1016/S2213-2600(19)30187-0. Epub 2019 Jun 6.

Reference Type: RESULT

PMID: 31178421 (View on PubMed)

Other Identifiers

SHIP001

Identifier Type: -

Identifier Source: org_study_id